Robert S. Rifkind, Who Defended a Libel Suit by Ariel Sharon, Dies at 88
In one of the biggest cases he worked on, he represented Time magazine when Mr. Sharon, Israel’s defense minister, sued it ...
Medscape2d
FDA Approves First and Only Therapy for IgG4-RD
Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...
The American Journal of Managed Care4d
Areas of Unmet Need Continue to Burden Patients With gMG
Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those ...
Myasthenia Gravis Foundation of America (MGFA) Annual MG Patient Conference Features Treatment Progress and Wellness Education
More than 500 members of the myasthenia gravis (MG) rare disease community will come together this week in-person and ...
Medscape12d
AAN 2025: Anticipating New Approaches in Myasthenia Gravis
Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.
FDA Approves Amgen's Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder
The FDA approved Amgen's Uplizna as the first treatment for IgG4-RD. The decision is backed by the MITIGATE trial, showing reduced flares and sustained efficacy.
Contract Pharma2d
Amgen’s UPLINZA Approved by FDA as Treatment for IgG4-RD
The U.S. Food and Drug Administration (FDA) has approved Amgen’s UPLIZNA as the first and only treatment for adults living ...